Navigation Links
Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
Date:5/20/2008

SEATTLE, May 20 /PRNewswire-FirstCall/ -- Omeros Corporation today announced that it has begun patient enrollment for the Phase 1 study of OMS201, the Company's second PharmacoSurgery(TM) drug product candidate, for use during urological surgery. At least 24 patients undergoing unilateral ureteroscopic removal of stones with a maximum diameter of 12 mm located in the renal-collecting system or ureter will be enrolled in the study.

"Advancing another PharmacoSurgery(TM) product candidate into clinical development marks an important milestone for Omeros," said Dr. Gregory A. Demopulos, Chairman and Chief Executive Officer of Omeros. "From our PharmacoSurgery(TM) platform, Omeros is developing a series of product candidates to improve clinical outcomes for surgical patients. The study for OMS201 expands our PharmacoSurgery(TM) platform into urological surgery."

OMS201 is one of the four clinical development programs in the Company's PharmacoSurgery(TM) platform. PharmacoSurgery(TM) product candidates are combinations of therapeutic agents designed to act simultaneously at multiple discrete targets to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery. The lead product candidate in the PharmacoSurgery(TM) platform is OMS103HP, which is currently in two Phase 3 clinical programs evaluating OMS103HP's safety and ability to improve postoperative joint function and reduce pain following arthroscopic surgery.

The Phase 1 randomized, double-blind, vehicle-controlled and parallel-assigned study of OMS201 is designed to evaluate the systemic absorption and safety of OMS201 in patients receiving primary treatment by endoscopic removal of urinary stones. OMS201, developed from Omeros' proprietary PharmacoSurgery(TM) platform, is designed for use during urological surgery, including uroendoscopic procedures such as ureteroscopy, cystoscopy and minima
'/>"/>

SOURCE Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
3. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
4. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
5. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
6. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
9. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
10. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
11. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), ... announced today that it acquired Bionik Laboratories, Inc., a ... completed the sale to qualified accredited investors of units ... gross proceeds of approximately $6.2 million. Shares of the ... the OTC Markets under the symbol "DWTPD" until FINRA,s ...
(Date:2/26/2015)... DALLAS , February 27, 2015 ... Review, H2 2014 market research report to its ... the Corneal Ulcers, therapeutic pipeline. The ... information on the therapeutic development for Corneal Ulcers. ... infections that includes bacterial infections, viral infections & ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015  IRIDEX ... will release its fourth quarter and full year 2014 financial ... 2015.   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, March 5, ... other business developments. Interested parties may access the ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... - Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company ... from two Phase III clinical trials for ... moderately severe,seasonal allergic rhinitis, commonly known as ... levels in both placebo and,PreHistin-treated patient groups, ...
... cell lung cancer -, LOS ANGELES, July 09, ... positive Phase III clinical,data published in the July ... that low expression of the biomarker,Excision-Repair Cross-Complementing 1 ... cancer (NSCLC) predicts for,sensitivity to cisplatin-based chemotherapy. ERCC-1 ...
Cached Medicine Technology:Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
(Date:2/27/2015)... FACE Skincare~Medical~Wellness, a multiaward-winning leader in ... combination to take fifteen years off of an ... new treatment introduced that is the first and ... improve lines and wrinkles on the Décolleté. This ... from the stubborn vertical lines between the upper ...
(Date:2/27/2015)... 27, 2015 Mediaplanet today announces the ... a campaign that aims to bring blood health and ... conversation. The stories in this edition go beyond the ... clinical care, hard-hitting advocacy, research and technological strides needed ... the American Cancer Society, approximately every 3 minutes ...
(Date:2/27/2015)... February 27, 2015 Glidewell Laboratories, ... the launch of its CloudPoint™ family ... digital production of monolithic zirconia crowns & bridges, ... of providing the CAD/CAM-produced restorations that doctors demand. ... through which cases can be scanned, managed and ...
(Date:2/27/2015)... Mirada, CA (PRWEB) February 27, 2015 ... patients who have suffered from injuries or diseases ... Healthpointe's team of physicians are located throughout Southern ... most-effective medical procedures to treat conditions related to ... and Dr. Edwin M. Ashley are board-certified and ...
(Date:2/27/2015)... Insight Accelerator Labs has partnered ... development of an in-line urine flow meter platform ... developed in direct response to current high cost ... error margins with potentially grave consequences. The company’s ... provide trending data analysis to signal ICU caregivers ...
Breaking Medicine News(10 mins):Health News:Face Skincare Announces New Combination Therapy 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 2Health News:Glidewell Laboratories Announces Release of CloudPoint™ FastScan™ and FastDesign™ 3Health News:Healthpointe is Now Performing Arthroscopic Surgery Techniques for Elbow, Hand and Wrist Injuries and Diseases, such as certain Ganglion Cysts 2Health News:Output Medical Joins Insight Accelerator Labs 2Health News:Output Medical Joins Insight Accelerator Labs 3
... and Rose Stein Institute for Research on Aging at the ... novel route to improving the symptoms of subsyndromal depression (SSD) ... video games that combine game play with exercise. In a ... improved mood and mental health-related quality of life in older ...
... ... ... , ... , , , , ...
... ... ... ... ...
... ... ... , ... Outlawing Health Insurance Monopolies Would Be Good for Doctors, Patients , ...
... therapy shows encouraging results for patients with locally advanced ... Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ... but aggressive types of cancer. Patients usually present with ... skull base such as eyes, optic nerves, brain. Between ...
... of the condition are higher in U.S. than Canada, ... Higher levels of obesity and inactivity, especially among women, ... States than in Canada, according to a new study. ... 2002-03 data from both countries and found that the ...
Cached Medicine News:Health News:Video games may help combat depression in older adults 2Health News:All Global Launches Physician Panels in Russia and Poland 2Health News:All Global Launches Physician Panels in Russia and Poland 3Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 2Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 3Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 4Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 5Health News:URAC Announces Open Public Comment Period for Expanded Independent Review Organization Accreditation 6Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 2Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 3
Quick Release buckle apron is user friendly with large support straps crisscrossing the back allowing proper placement of the belt at your waist....
... Our unique velcro design ... for additional support and comfort. ... two velcro flaps aid in ... A comfortable fit is attained ...
This one of a kind design also provides full body protection. Split down each side, like a poncho, this apron is simple to put on and take off. Available with an orthopedic wide belt or buckle belt....
Gonad shields protect the reproductive organs. Available in male and female models. One size fits all....
Medicine Products: